aTyr Pharma, Inc. (NASDAQ:ATYR) Receives $17.00 Average Target Price from Analysts

aTyr Pharma, Inc. (NASDAQ:ATYR) has been given an average recommendation of “Hold” by the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.00.

ATYR has been the topic of a number of research reports. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Finally, Freedom Capital upgraded shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th.

Insider Buying and Selling

In other aTyr Pharma news, Director Paul Schimmel bought 100,000 shares of aTyr Pharma stock in a transaction dated Wednesday, May 27th. The stock was acquired at an average cost of $0.50 per share, with a total value of $50,000.00. Following the completion of the acquisition, the director owned 779,143 shares of the company’s stock, valued at approximately $389,571.50. This represents a 14.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.75% of the company’s stock.

Hedge Funds Weigh In On aTyr Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in ATYR. Bank of America Corp DE raised its stake in aTyr Pharma by 139.6% during the 1st quarter. Bank of America Corp DE now owns 303,559 shares of the company’s stock valued at $237,000 after acquiring an additional 176,859 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of aTyr Pharma in the 1st quarter valued at approximately $32,000. Virtu Financial LLC purchased a new position in shares of aTyr Pharma in the 4th quarter valued at approximately $62,000. ADAR1 Capital Management LLC grew its stake in shares of aTyr Pharma by 35.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock valued at $40,000 after purchasing an additional 13,385 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $603,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Price Performance

NASDAQ ATYR opened at $0.49 on Tuesday. The company has a fifty day moving average of $0.51 and a two-hundred day moving average of $0.71. The company has a market capitalization of $47.62 million, a PE ratio of -0.67 and a beta of 0.52. aTyr Pharma has a 1 year low of $0.40 and a 1 year high of $6.50.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. On average, research analysts expect that aTyr Pharma will post -0.66 earnings per share for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.